RNS Filings

As of April 5, 2017, LivaNova is no longer listed on the London Stock Exchange.

Apr 05, 2017

LivaNova Plc: Cancellation of listing and cancellation of admission to trading of LivaNova Plc Ordinary Shares.

5 April 2017 Further to LivaNova Plc’s (“LivaNova”) announcement on 23 February 2017 that it had made an application (i) to the UK Financial Conduct Authority for the cancellation of the standard listing of LivaNova’s ordinary shares of £1 per share (ISIN: GB00BYMT0J19) (the “Shares”) on the Official List of the UK Listing Authority and (ii) to the London Stock Exchange plc (the “LSE”) to cancel the admission to trading of the Shares on the Main Market of the LSE (together, the ... Read More
  
Apr 03, 2017

LivaNova PLC: Total Voting Rights

3 April 2017 Total Voting Rights and Share Capital In accordance with Disclosure and Transparency Rule 5.6, LivaNova PLC (the “Company”) hereby notifies the market that as of 31 March 2017, the Company’s capital consists of 48,184,737 ordinary shares of £1.00 each. The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company is 48,184,737. This figure may be used by shareholders as the denominator for the calculations by which they wil... Read More
  
Mar 31, 2017

LivaNova Plc: Resignation of Chief Financial Officer

31 March 2017 LivaNova Plc – Resignation of Chief Financial Officer On 29 March 2017, Vivid Sehgal, a person discharging managerial responsibility, resigned his position as Chief Financial Officer of LivaNova Plc (“LivaNova”), effective on 31 May 2017, to pursue other opportunities. LivaNova has commenced a search for Mr. Sehgal’s successor. Mr. Sehgal will make himself available after 31 May 2017, if needed, to support the transition of his responsibilities to his successor.On 30 Mar... Read More
  
Mar 29, 2017

LivaNova PLC: TR-1 Notification of Major Interest in Shares

Please click here to view the RNS filing.... Read More
  
Mar 29, 2017

LivaNova to Host Conference Call for First Quarter 2017 Results

London, 29 March 2017 – LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, will host a conference call to discuss its first quarter results on Wednesday, 3 May 2017 at 8 a.m. Central Daylight Time (2 p.m. BST). The Company will release its first quarter results earlier that morning, before the open of the U.S. financial markets. A live webcast of the conference call will be available on the Investor Relations section of Liva... Read More
  
Mar 23, 2017

LivaNova PLC: Extension of the Period for Cover of Costs to Cancel Depositary Interests

Extension of the Period for Cover of Costs to Cancel Depositary Interests in respect of Intended Cancellation of Ordinary Shares from Listing on the Official List and Admission to Trading on the London Stock Exchange23 March 2017LivaNova Plc Extension of the Period for Cover of Costs to Cancel Depositary Interests in respect of Intended Cancellation of Ordinary Shares from Listing on the Official List and Admission to Trading on the London Stock ExchangeLivaNova Plc (“LivaNova”) refers... Read More
  
Mar 16, 2017

LivaNova PLC: Director/PDMR Shareholding

Please click here to view the RNS filing.... Read More
  
Mar 14, 2017

LivaNova PLC: Director/PDMR Shareholding

Please click here to view the RNS filing.... Read More
  
Mar 14, 2017

LivaNova PLC: Director/PDMR Shareholding

Please click here to view the RNS filing.... Read More
  
Mar 06, 2017

LivaNova PLC: Director/PDMR Shareholding

LONDON-- BUSINESS WIRE PDMR DEALING NOTIFICATION TEMPLATE Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 1   Details of the person discharging manag... Read More
  
Mar 01, 2017

LivaNova 10-K filing announcement

LivaNova Annual Report Form 10-K filingLondon, March 1, 2017 – LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that it filed an Annual Report on Form 10-K under the U.S. Securities Exchange Act of 1934 for LivaNova for the period January 1, 2016 to December 31, 2016 (“Form 10-K”) with the U.S. Securities Exchange Commission (the “SEC”) on 1 March, 2017. The Form 10-K can be found on the SEC’s website at www.s... Read More
  
Mar 01, 2017

LivaNova PLC: Total Voting Rights

In accordance with Disclosure and Transparency Rule 5.6, LivaNova PLC (the “Company”) hereby notifies the market that as of 28 February 2017, the Company’s capital consists of 48,178,729 ordinary shares of £1.00 each. The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company is 48,178,729. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their i... Read More
  
Mar 01, 2017

LivaNova Reports Fourth Quarter and Full-Year 2016 Results

London, March 1, 2017 – LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that, on 1 March 2017, LivaNova filed with the U.S. Securities and Exchange Commission its Current Report on Form 8-K, a copy of which can be found at www.sec.gov. A copy of the Form 8-K is being submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at http://www.morningsta... Read More
  
Mar 01, 2017

LivaNova Plc – Product remediation plan related to 3T Heater Cooler device

In respect of its consolidated financial statements under US GAAP as of and for the year ended 31 December 2016, LivaNova PLC (the “Company”) has recognized a liability under US GAAP in the amount of $33.5 million for a product remediation plan related to its 3T Heater Cooler device. The remediation plan developed by the Company consists primarily of a modification of the 3T Heater Cooler design to include internal sealing and the addition of a vacuum system to new and existing devices. ... Read More
  
Feb 28, 2017

LivaNova Annual Short Term Incentive Plan and CEO’s Compensation

London, February 28, 2017 – LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that, on 28 February 2017, LivaNova filed with the U.S. Securities and Exchange Commission its Current Report on Form 8-K, a copy of which can be found at www.sec.gov. A copy of the Form 8-K is being submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at http://www.m... Read More
  
Feb 23, 2017

LivaNova PLC: Director/PDMR Shareholding

Please click here to view the RNS filing.... Read More
  
Feb 23, 2017

LivaNova PLC: Intended Delisting and Cancellation of Ordinary Shares from London Stock Exchange

LivaNova Plc Intended Cancellation of Ordinary Shares from Listing on the Official List and of Admission to Trading on the London Stock ExchangeLivaNova Plc ("LivaNova") announces today that it has made applications (i) to the UK Financial Conduct Authority (the "FCA") for the cancellation of the standard listing of LivaNova's ordinary shares of £1 per share (ISIN: GB00BYMT0J19) (the "Shares") on the Official List of the UK Listing Authority and (ii) to the London Stock Exchange plc (the "LSE") ... Read More
  
Feb 01, 2017

LivaNova PLC: Director/PDMR Shareholding

Please click here to view the RNS filing.... Read More
  
Feb 01, 2017

LivaNova PLC: Total Voting Rights

1 February 2017 TOTAL VOTING RIGHTS AND SHARE CAPITAL In accordance with Disclosure and Transparency Rule 5.6, LivaNova PLC (the “Company”) hereby notifies the market that as of 31 January 2017, the Company’s capital consists of 48,178,155 ordinary shares of £1.00 each. The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company is 48,178,155. This figure may be used by shareholders as the denominator for the calculations by which t... Read More
  
Jan 25, 2017

LivaNova to Host Conference Call for Fourth Quarter 2016 Results

LONDON--(BUSINESS WIRE)--Jan. 25, 2017-- LivaNova PLC (NASDAQ:LIVN; LSE:LIVN) ("LivaNova" or the "Company"), a market-leading medical technology company, will host a conference call to discuss its fourth quarter results on Wednesday, March 1, 2017 at 8:00 am Central Time (1:00 pm GMT). The Company will release its fourth quarter results earlier that morning, before the open of the U.S. financial markets. A live webcast of the confe... Read More
  
Jan 10, 2017

LivaNova PLC: Holding(s) in Company

Please click here to view the RNS filing.... Read More
  
Jan 06, 2017

LivaNova PLC: Holding(s) in Company

Please click here to view the RNS filing.... Read More
  
Jan 04, 2017

LivaNova PLC: Director/PDMR Shareholding

Please click here to view the RNS filing.... Read More
  
Jan 03, 2017

Total Voting Rights and Share Capital

03 January 2017 TOTAL VOTING RIGHTS AND SHARE CAPITAL In accordance with Disclosure and Transparency Rule 5.6, LivaNova PLC (the "Company") hereby notifies the market that as of 30 December 2016, the Company's capital consists of 48,156,690 ordinary shares of £1.00 each.  The Company does not hold any shares in treasury.Therefore, the total number of voting rights in the Company is 48,156,690.  This figure may be used by shareholders as the denominator for the calculations by which the... Read More